Company: BDJ
Filing Date: 2025-09-04
Form Type: N-CSRS
Source: 0001193125-25-196068
Chunk: 15

Company: BlackRock Enhanced Equity Dividend Trust
Filing Date: 2025-09-04
Form: N-CSRS
Chunk 15
---
.95% |                        8.41% |   9.19% |    5.68% |
| Trust at Market Price(a)(b)              |   14.04 |                        12.68 |   10.36 |     5.55 |
| MSCI ACWI ex USA Call Overwrite Index(c) |   14.46 |                        15.58 |    8.81 |      N/A |
| MSCI ACWI ex USA Index (Net)(d)          |   17.90 |                        17.72 |   10.13 |     6.12 |

| (a) 
 (b) 
 (c) | All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.                                                                                                                       
 TheTrust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.                                                        
 An index that incorporates an option overlay component on the MSCI ACWI ex USA Index with a 45% overwrite level. The benchmark commenced on December 31, 2018 and thereforethe benchmark does not have 10-year returns. |
|:----|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (d) | An index that captures large- and mid-cap representation across certain developed markets countries (excluding the U.S.) and certain emerging markets countries.                                                        |

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.
Past performance is not an indication of future results. The Trust is presenting the performance of one or more indices for informational purposes only. The Trust is actively managed and does not seek to track or replicate the performance of any index. The index performance shown is not intended to be indicative of the Trust’s investment strategies, portfolio components or past or future performance. More information about the Trust’s historical performance can be found in the “Closed End Funds” section of blackrock.com . The following discussion relates to the Trust’s relative performance based on NAV: What factors influenced performance? Security selection in the industrials, healthcare and consumer staples sectors detracted from relative performance over the period. In terms of individual detractors, sentiment around Danish pharmaceutical company Novo Nordisk sentiment was negatively impacted after clinical trial results for its new weight loss drug Cagrisema failed to show superior efficacy relative to competitor Eli Lilly’s treatment, raising questions on the drug’s commercialization prospects. In addition, Eli Lilly’s weight-loss drugs Z